CVRx to Showcase Barostim at William Blair Growth Stock Conference
Event summary
- CVRx to present at William Blair 46th Annual Growth Stock Conference on June 2, 2026, at 10:40 a.m. CT.
- Live webcast available at ir.cvrx.com, with archived version accessible post-event.
- Barostim is the first FDA-approved neuromodulation device for heart failure patients.
- Device holds CE Mark approval for heart failure and resistant hypertension in the EU.
The big picture
CVRx's participation in the William Blair conference underscores its push to expand Barostim's market reach. The device's FDA Breakthrough Device designation and CE Mark approval position it as a key player in neuromodulation for cardiovascular diseases. The strategic focus now shifts to commercial execution and potential geographic expansion.
What we're watching
- Commercialization Progress
- How CVRx will leverage conference exposure to accelerate Barostim adoption in the U.S. and EU markets.
- Regulatory Expansion
- Whether CVRx can secure additional approvals for Barostim in other high-potential regions.
- Competitive Positioning
- The pace at which CVRx can differentiate Barostim in a growing neuromodulation landscape.